[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aerospace Center Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100651244","motor-cortex-stimulation-for-post-stroke-thalamic-pain-100651244",false,"NCT07758829","Motor Cortex Stimulation for Post-Stroke Thalamic Pain","A Study on Mechanisms and Predictive Factors of Motor Cortex Stimulation for Post-Stroke Thalamic Pain Based on Multimodal Imaging","Inclusion Criteria:\n\n* Age between 18 and 80 years. Diagnosed with chronic post-stroke central pain with a pain duration of at least 1 year, with stroke localized to the thalamus.\n\nVisual Analog Scale (VAS) pain score ≥ 5 at baseline. Poor response to or intolerance of conventional pharmacotherapy for pain. Medically suitable for surgical treatment (no coagulopathy, no infection at surgical site, no severe psychiatric disorders, etc.).\n\nVoluntarily agrees to receive motor cortex stimulation (MCS) treatment. Able to communicate effectively with researchers and willing to comply with all study requirements.\n\nSufficient cognitive ability to use the patient programmer and patient programmer charger.\n\nExclusion Criteria:\n\n* History of alcohol, drug, or substance abuse or dependence within the past 12 months.\n\nTrigeminal neuralgia or atypical facial pain. Advanced cardiovascular or other systemic disease that precludes surgical intervention.\n\nPrior history of ablative or related intracranial surgery. Presence of other neurological disorders, such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, or brain\u002Fspinal cord tumors.\n\nImplanted drug pump and\u002For another implantable device (e.g., cardiac pacemaker, defibrillator, cochlear implant, other neurostimulation systems such as spinal cord stimulator or deep brain stimulator).\n\nMetastatic malignancy or untreated localized malignancy. Pregnancy, breastfeeding, planned pregnancy, or women of childbearing potential without reliable contraceptive measures.\n\nSevere depression or anxiety (as determined by clinical assessment). Any other condition deemed unsuitable for participation by the investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to investigate the mechanisms and predictive factors of motor cortex stimulation (MCS) for treating post-stroke thalamic pain, a challenging central neuropathic pain condition. Approximately 25% of patients show no short-term response to MCS, and about 20% experience long-term efficacy decay, yet the underlying analgesic mechanisms remain unclear and objective predictive biomarkers are lacking.\n\nThis study aims to answer the following main questions:\n\nHow does MCS modulate thalamic pain through the coordinated interaction of structural connectivity, functional network dynamics, and metabolic balance in the brain? What are the distinct neuroimaging characteristics that differentiate short-term non-responders, long-term responders, and those with long-term efficacy decay? Which multimodal imaging biomarkers can reliably predict short-term and long-term MCS efficacy? Participants will undergo a two-stage MCS surgical procedure. In stage I, epidural electrodes are implanted over the motor cortex, followed by a 2-week external trial stimulation. Participants who achieve a ≥50% reduction in Visual Analog Scale (VAS) pain score will proceed to stage II, receiving an implanted pulse generator for long-term stimulation. Those who do not respond in the short term will have the electrodes removed without undergoing stage II implantation.\n\nAll participants will complete baseline clinical assessments and multimodal MRI scans (including T1, DTI, resting-state fMRI, and MRS) before surgery. Participants who receive the permanent implant will undergo follow-up clinical evaluations and repeat MRI scans at 3 and 6 months post-surgery.\n\nResearchers will compare imaging features across three outcome groups-short-term non-responders, long-term responders, and long-term decay group-to identify predictive biomarkers. Multimodal imaging data will be integrated using LASSO regression to build prediction models for both short-term screening and long-term efficacy warning.\n\nThis research is expected to establish a \"mechanism exploration - efficacy prediction - clinical decision\" paradigm, providing objective imaging-based evidence to guide patient selection and postoperative management for MCS treatment.",[27,28,29,30],"Central Post-stroke Pain","Stroke","Electric Stimulation Therapy","Multimodal Imaging",[32,33,34,35,36,37],"Post-Stroke Thalamic Pain","Motor Cortex Stimulation","Neuromodulation","Multimodal Magnetic Resonance Imaging","Predictive Biomarkers","Brain Networks","NOT_YET_RECRUITING","2026-08-06",{"date":41,"type":42},"2026-08-11","ACTUAL",{"date":44,"type":21},"2026-09-01",{"date":46,"type":21},"2029-06-30",{"name":48,"class":49},"Aerospace Center Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100622761","individualized-open-lung-ventilation-and-postoperative-pulmonary-complications-in-thoracic-surgery-100622761","NCT07387822","Individualized Open Lung Ventilation and Postoperative Pulmonary Complications in Thoracic Surgery","Effect of Individualized Versus Standardized Open-Lung Ventilation on Postoperative Pulmonary Complications in Thoracic Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Body mass index between 18 and 30 kg\u002Fm².\n* Scheduled for elective video-assisted thoracoscopic surgery (VATS).\n* Expected duration of one-lung ventilation longer than 1 hour.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Emergency surgery or reoperation.\n* History of severe pulmonary disease, including chronic obstructive pulmonary disease, pulmonary fibrosis, severe emphysema, pulmonary bullae, pneumothorax, or uncontrolled asthma.\n* History of heart failure or coronary artery disease.\n* Previous thoracic surgery or mechanical ventilation within 1 month before surgery.\n* Planned postoperative mechanical ventilation.\n* Bilateral thoracic surgery.\n* Participation in another interventional clinical trial.\n* Conversion to open thoracotomy during surgery.","75 Years",{"count":59,"type":21},352,[24],"This prospective, single-center, randomized controlled trial aims to evaluate the efficacy of an intraoperative \"Individualized Open Lung Ventilation\" strategy compared to a standard lung-protective ventilation strategy in patients undergoing thoracic surgery.\n\nOne-lung ventilation (OLV) is essential for thoracic surgery but can cause lung injury. While standard care often uses fixed ventilation parameters, this study investigates whether personalizing Positive End-Expiratory Pressure (PEEP) to achieve the lowest driving pressure can reduce the incidence of postoperative pulmonary complications (PPCs) within 7 days after surgery.",[63,64,65],"Postoperative Pulmonary Complications (PPCs)","One-lung Ventilation (OLV)","Thoracic Surgery, Video Assisted",[67,68,69,70,71,72],"Individualized Open Lung Ventilation","Driving Pressure","PEEP Titration","Lung Recruitment Maneuver","Lung Protective Ventilation","Video-Assisted Thoracic Surgery","2026-01-30",{"date":75,"type":42},"2026-02-04",{"date":77,"type":21},"2026-02-10",{"date":79,"type":21},"2026-05-10",{"name":48,"class":49},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":81},"100622034","proactive-temperature-management-in-crs-hipec-for-prevention-of-delirium-100622034","NCT07378371","Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium","Proactive Temperature Management and Delirium After Cytoreductive Surgery With HIPEC: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients (aged 18-80 years).\n\nAmerican Society of Anesthesiologists (ASA) physical status of I to III.\n\nScheduled for elective Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Pseudomyxoma Peritonei (PMP).\n\nWritten informed consent obtained from the participant or legally authorized representative.\n\nExclusion Criteria:\n\n* Known diagnosis of dementia, major neurocognitive disorder, or severe psychiatric illness (e.g., schizophrenia) documented in the medical record.\n\nAcute central nervous system pathology likely to confound delirium assessment (e.g., recent stroke, active seizure disorder, or traumatic brain injury).\n\nSevere sensory or language barriers precluding valid cognitive screening (e.g., profound deafness or blindness, or language barriers not correctable with translation).\n\nPreoperative coma, mechanical ventilation, or deep sedation precluding reliable baseline assessment.\n\nEmergency surgery or repeat CRS-HIPEC during the same hospital admission.\n\nHistory of alcohol or substance abuse likely to precipitate withdrawal symptoms.",{"count":90,"type":21},174,[24],"This randomized controlled trial evaluates the efficacy of a proactive Goal-Directed Temperature Management (GDTM) protocol in reducing postoperative delirium among patients undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for pseudomyxoma peritonei.\n\nCRS-HIPEC presents a unique physiological challenge characterized by a biphasic thermal trajectory: potential hypothermia during extensive surgery followed by rapid iatrogenic hyperthermia during perfusion. This study compares a standardized GDTM strategy-which incorporates strict normothermia maintenance and anticipatory pre-cooling prior to perfusion-against standard reactive thermal management. The primary objective is to determine if optimized thermoregulation can attenuate thermal variability and improve early neurocognitive recovery.",[94,95],"Pseudomyxoma Peritonei","Postoperative Delirium (POD)",[97,98,99,100,101],"Cytoreductive Surgery","HIPEC","Hyperthermic Intraperitoneal Chemotherapy","Temperature Management","Goal-Directed Therapy","2026-01-27",{"date":73,"type":42},{"date":105,"type":21},"2026-02-01",{"date":107,"type":21},"2026-05-01",{"name":48,"class":49},""]